evidence table

Resveratrol Cardiovascular Randomized Trial Evidence Table

Name: Resveratrol Cardiovascular Randomized Trial Evidence Table
Creator: Migaku
License: https://creativecommons.org/licenses/by/4.0/

Structured evidence table for Resveratrol Cardiovascular Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topic	claim	evidence level	citation	source
Resveratrol Cardiovascular Randomized Trial	The main aim of this systematic review is to comprehensively evaluate and synthesize the current scientific evidence on the role of anthocyanins, curcumin, and resveratrol in the prevention and management of metabolic disorders, with a focus on obesity, type 2 diabetes, and dyslipidemia.	1	Gazda P (2026)	The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review.
Resveratrol Cardiovascular Randomized Trial	The analyzed studies demonstrated that anthocyanin supplementation (up to 320 mg/day) was associated with reductions in inflammatory markers such as IL-6 and TNF-α, improvements in HDL cholesterol, and modest reductions in HbA1c (~0.3-0.5%).	1	Gazda P (2026)	The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review.
Resveratrol Cardiovascular Randomized Trial	Curcumin supplementation was associated with decreases in body weight (up to 0.82 kg), BMI (up to 0.30 kg/m 2 ), triglycerides, total cholesterol, and fasting glucose levels.	1	Gazda P (2026)	The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review.
Resveratrol Cardiovascular Randomized Trial	Metabolic disorders such as obesity, type 2 diabetes, and lipid disorders are major health challenges worldwide.	1	Gazda P (2026)	The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review.
Resveratrol Cardiovascular Randomized Trial	Background and aims Menopause is an important cardiovascular risk factor in women likely due to marked estrogen decline.	2	Gonçalinho GHF (2026)	The effects of resveratrol on endothelial progenitor cells and apoptosis biomarkers in postmenopausal women with chronic coronary heart disease: a randomized controlled trial.
Resveratrol Cardiovascular Randomized Trial	Conclusion Resveratrol increased serum Bcl-2 and cIAP2, and also reduced caspase 9 and circulating EPCs in postmenopausal women with chronic CHD, likely unrelated to circulating SIRT1 and SIRT3.	2	Gonçalinho GHF (2026)	The effects of resveratrol on endothelial progenitor cells and apoptosis biomarkers in postmenopausal women with chronic coronary heart disease: a randomized controlled trial.
Resveratrol Cardiovascular Randomized Trial	The effects of resveratrol treatment in this population group should be assessed with caution, as a reduction in EPCs is associated with impaired endothelial function and an increased risk of cardiovascular disease.	2	Gonçalinho GHF (2026)	The effects of resveratrol on endothelial progenitor cells and apoptosis biomarkers in postmenopausal women with chronic coronary heart disease: a randomized controlled trial.
Resveratrol Cardiovascular Randomized Trial	Estrogens affect key processes in atherosclerosis, maintaining endothelial integrity by inhibiting endothelial apoptosis and promoting regeneration through endothelial progenitor cells (EPCs).	2	Gonçalinho GHF (2026)	The effects of resveratrol on endothelial progenitor cells and apoptosis biomarkers in postmenopausal women with chronic coronary heart disease: a randomized controlled trial.